Preprint Article Version 2 Preserved in Portico This version is not peer-reviewed

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib

Paweł Robak
,
Dariusz Jarych
ORCID logo ,
Damian Mikulski
,
Izabela Dróżdż
ORCID logo ,
Edyta Węgłowska
,
Aleksandra Kotkowska
,
Małgorzata Misiewicz
,
Piotr Smolewski
,
Konrad Stawiski
,
Wojciech Fendler
ORCID logo ,
Janusz Szemraj
ORCID logo ,
Tadeusz Robak
* ORCID logo
Version 1 : Received: 9 December 2020 / Approved: 11 December 2020 / Online: 11 December 2020 (15:50:15 CET)
Version 2 : Received: 23 January 2021 / Approved: 25 January 2021 / Online: 25 January 2021 (13:17:31 CET)

A peer-reviewed article of this Preprint also exists.

Robak, P.; Jarych, D.; Mikulski, D.; Dróżdż, I.; Węgłowska, E.; Kotkowska, A.; Misiewicz, M.; Smolewski, P.; Stawiski, K.; Fendler, W.; Szemraj, J.; Robak, T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers 2021, 13, 951. Robak, P.; Jarych, D.; Mikulski, D.; Dróżdż, I.; Węgłowska, E.; Kotkowska, A.; Misiewicz, M.; Smolewski, P.; Stawiski, K.; Fendler, W.; Szemraj, J.; Robak, T. The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib. Cancers 2021, 13, 951.

Abstract

Proteasome inhibitors, like bortezomib, play a key role in the treatment of multiple myeloma (MM); however, most patients eventually relapse and eventually show multiple drug resistance, and the molecular mechanisms of this resistance remain unclear. The present study examines the expression of previously-described genes that may influence resistance to bortezomib treatment at the mRNA level (ABCB1, CXCR4, MAF, MARCKS, POMP, PSMB5, RPL5, TXN and XBP1). mRNA expression was determined in 73 MM patients treated with bortezomib-based regimens (30 bortzomib-sensitive and 43 bortezomib-refractory patients) and 11 healthy controls. RPL5 was significantly down-regulated in multiple myeloma patients as compared with healthy controls. Moreover, POMP was significantly up-regulated in MM patients refractory to bortezomib-based treatment. In multivariate analysis, high expression of PSMB5 and CXCR and autologous stem cell transplantation were independent predictors of progression-free survival, and high expression of POMP and RPL5 was associated with shorter overall survival.

Keywords

ABCB1; bortezomib; CXCR4; gene expression; MAF; MARCKS; multiple myeloma; mRNA; POMP; PSMB5; refractory; RPL5; TXN; XBP1; sensitive

Subject

Biology and Life Sciences, Biochemistry and Molecular Biology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.